secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-07-23T11:00:14+00:00
Accession:  0001645113-26-000063
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure Q2 net revenue $183.6M (+16% YoY); raises FY 2026 guidance
-------------------------------------------------------------------

- Net revenue $183.6M, up 16% YoY; net loss $15.7M ($0.13 loss per share).
- Adjusted EBITDA $10.8M; gross margin 78% vs 74% a year ago.
- FY 2026 revenue guidance raised to $710M-$725M (prev $690M-$710M); adjusted EBITDA guidance raised to $0M-$15M.
- CE Mark received for Optune Pax for locally advanced pancreatic cancer; 285 active patients on Optune Pax in U.S.
- Global active patients 5,128, up 11% YoY for Optune Gio; Optune Lua active patients up 51%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000063/0001645113-26-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000063/nvcr-20260723.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer